DEA's Mysterious Memo on Dr. Konen: Details? What Details?
Published Date: 8/20/2025
Notice
Summary
Dr. Andrew Konen from Dallas lost his DEA license because he wrote lots of prescriptions for strong drugs in ways that weren’t legal or safe. He didn’t show up to defend himself, so the government decided to revoke his registration and deny any future applications. This means he can’t legally prescribe controlled substances anymore, starting now.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Konen
The Drug Enforcement Administration revoked Andrew Konen, M.D.'s DEA certificate of registration (BK4924139) and denied all pending registration applications he had in Texas. The OSC that led to this action was issued August 12, 2024, and the Decision and Order was published August 20, 2025.
Default Rule: Missed Deadlines Can Forfeit Hearing
Under DEA rules (21 CFR 1301.37(d) and 1301.43), a person served with an Order to Show Cause has 30 days to request a hearing and answer the allegations; an unexcused default can be deemed a waiver of the right to a hearing and an admission of the OSC's factual allegations. The final rule implementing this framework became effective December 14, 2022, and was applied in this case after missed prehearing deadlines in September–October 2024.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-15865, Agency Information Collection Activity: Application for Disability Compensation and Related Compensation Benefits
The VA wants your thoughts on updating the form veterans use to apply for disability benefits. This is a chance to help make the process smoother and easier for those who served. You’ve got 60 days to share your feedback—no money changes yet, just a heads-up to improve the paperwork!
Next: 2025-15867, Kenneth Pherson, D.O.; Decision and Order
Kenneth Pherson, D.O., lost his DEA registration because he no longer has permission to handle controlled substances in Florida. He didn’t ask for a hearing after being notified, so the DEA moved forward and officially revoked his registration. This means Dr. Pherson can’t legally prescribe or manage controlled drugs anymore, effective immediately.